NCT05722327 2026-03-04
Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
M.D. Anderson Cancer Center
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.